4.5 Article

COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers

期刊

VACCINE
卷 40, 期 3, 页码 494-502

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2021.11.094

关键词

-

资金

  1. National Center for Immunization and Respiratory Diseases
  2. Centers for Disease Control and Prevention [75D30120R68013, 75D30120C08379, 75D30120C08150]

向作者/读者索取更多资源

This multi-center prospective cohort study examined the impact of vaccine intention, prior SARS-CoV-2 positivity, and occupation on COVID-19 vaccine uptake among essential workers. The results showed that knowledge, attitudes, and practices strongly predicted vaccine uptake, particularly positive attitudes about safety and effectiveness of the vaccine. Participants with prior SARS-CoV-2 infection and first responders were more vaccine reluctant. The study suggests that targeted messaging about the vaccine's safety and effectiveness may increase vaccine uptake among reluctant and reachable participants.
Introduction: In a multi-center prospective cohort of essential workers, we assessed knowledge, attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, and occupation, and their impact on vaccine uptake over time. Methods: Initiated in July 2020, the HEROES-RECOVER cohort provided socio-demographics and COVID-19 vaccination data. Using two follow-up surveys approximately three months apart, COVID-19 vaccine KAP, intention, and receipt was collected; the first survey categorized participants as reluctant, reachable, or endorser. Results: A total of 4,803 participants were included in the analysis. Most (70%) were vaccine endorsers, 16% were reachable, and 14% were reluctant. By May 2021, 77% had received at least one vaccine dose. KAP responses strongly predicted vaccine uptake, particularly positive attitudes about safety (aOR = 5.46, 95% CI: 1.4-20.8) and effectiveness (aOR = 5.0, 95% CI: 1.3-19.1). Participants' with prior SARS-CoV-2 infection were 22% less likely to believe the COVID-19 vaccine was effective compared with uninfected participants (aOR 0.78, 95% CI: 0.64-0.96). This was even more pronounced in first responders compared with other occupations, with first responders 42% less likely to believe in COVID-19 vaccine effectiveness (aOR = 0.58, 95% CI 0.40-0.84). Between administrations of the two surveys, 25% of reluctant, 56% reachable, and 83% of endorser groups received the COVID-19 vaccine. The reachable group had large increases in positive responses for questions about vaccine safety (10% of vaccinated, 34% of unvaccinated), and vaccine effectiveness (12% of vaccinated, 27% of unvaccinated). Discussion: Our study demonstrates attitudes associated with COVID-19 vaccine uptake and a positive shift in attitudes over time. First responders, despite potential high exposure to SARS-CoV-2, and participants with a history of SARS-CoV-2 infection were more vaccine reluctant. Conclusions: Perceptions of the COVID-19 vaccine can shift over time. Targeting messages about the vaccine's safety and effectiveness in reducing SARS-CoV-2 virus infection and illness severity may increase vaccine uptake for reluctant and reachable participants. (C) 2021 The Authors. Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States

Mark W. Tenforde, Wesley H. Self, Yuwei Zhu, Eric A. Naioti, Manjusha Gaglani, Adit A. Ginde, Kelly Jensen, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Tresa McNeal, Shekhar Ghamande, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Matthew E. Prekker, Heidi L. Erickson, Michelle N. Gong, Amira Mohamed, Nicholas J. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Arnold S. Monto, Akram Khan, Catherine L. Hough, Laurence W. Busse, Caitlin ten Lohuis, Abhijit Duggal, Jennifer G. Wilson, Nida Qadir, Steven Y. Chang, Christopher Mallow, Carolina Rivas, Hilary M. Babcock, Jennie H. Kwon, Matthew C. Exline, Mena M. Botros, Adam S. Lauring, Nathan Shapiro, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Todd W. Rice, Ian D. Jones, William B. Stubblefield, Adrienne Baughman, Kelsey N. Womack, Jillian P. Rhoads, Christopher J. Lindsell, Kimberly W. Hart, Caitlin Turbyfill, Samantha Olson, Nancy Murray, Katherine Adams, Manish M. Patel

Summary: Among hospitalized adults, the effectiveness of the two-dose mRNA vaccine against COVID-19-associated hospitalization decreased from 90% to 82% after 6 months post-vaccination. This study highlights the limited long-term durability of protection provided by the COVID-19 mRNA vaccines against hospitalization.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial

Manjusha Gaglani, Sara S. Kim, Allison L. Naleway, Min Z. Levine, Laura Edwards, Kempapura Murthy, Kayan Dunnigan, Tnelda Zunie, Holly Groom, Sarah Ball, Zuha Jeddy, Danielle Hunt, Meredith G. Wesley, Suryaprakash Sambhara, Shivaprakash Gangappa, Lauren Grant, Weiping Cao, F. Liaini Gross, Margarita Mishina, Alicia M. Fry, Mark G. Thompson, Fatimah S. Dawood, Brendan Flannery

Summary: Healthcare personnel who received two consecutive seasons of quadrivalent recombinant-hemagglutinin influenza vaccine showed higher levels of post-vaccination antibodies compared to those who received egg-based inactivated vaccine. However, this effect was not observed in those who received cell-culture vaccines. This study highlights the importance of gradually increasing the dose of influenza vaccine over consecutive seasons for improved immunogenicity.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021-2022 Influenza Season

Ashley M. Price, Brendan Flannery, H. Keipp Talbot, Carlos G. Grijalva, Karen J. Wernli, C. Hallie Phillips, Arnold S. Monto, Emily T. Martin, Edward A. Belongia, Huong Q. McLean, Manjusha Gaglani, Manohar Mutnal, Krissy Moehling Geffel, Mary Patricia Nowalk, Sara Y. Tartof, Ana Florea, Callie McLean, Sara S. Kim, Manish M. Patel, Jessie R. Chung

Summary: In the 2021-2022 season, influenza activity in the United States was mild enough to estimate the effectiveness of the influenza vaccine. Researchers found that the vaccine had an effectiveness of 36% against outpatient acute illness caused by A(H3N2) viruses.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022

Mark W. Tenforde, Manish M. Patel, Nathaniel M. Lewis, Katherine Adams, Manjusha Gaglani, Jay S. Steingrub, Nathan Shapiro, Abhijit Duggal, Matthew E. Prekker, Ithan D. Peltan, David N. Hager, Michelle N. Gong, Matthew C. Exline, Adit A. Ginde, Nicholas M. Mohr, Christopher Mallow, Emily T. Martin, H. Keipp Talbot, Kevin W. Gibbs, Jennie H. Kwon, James D. Chappell, Natasha Halasa, Adam S. Lauring, Christopher J. Lindsell, Sydney A. Swan, Kimberly W. Hart, Kelsey N. Womack, Adrienne Baughman, Carlos G. Grijalva, Wesley H. Self

Summary: During the 2021-2022 US influenza season, circulating A(H3N2) viruses were antigenically different from the vaccine. The vaccine effectiveness against hospitalized illness was 26% (95% CI: -14-52%) for adults 18-64 years old and -3% (95% CI: -54-31%) for adults ≥ 65 years old. Our study showed that the influenza vaccine had some effectiveness in preventing hospitalization among immunocompetent adults aged 18-64, but provided no significant protection for adults ≥ 65.

CLINICAL INFECTIOUS DISEASES (2023)

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses

Meghan K. Herring, James K. Romine, Meredith G. Wesley, Katherine D. Ellingson, Sarang K. Yoon, Alberto J. Caban-Martinez, Jennifer Meece, Manjusha Gaglani, Lauren Grant, Lauren E. W. Olsho, Harmony L. Tyner, Allison L. Naleway, Sana M. Khan, Andrew L. Phillips, Natasha Schaefer Solle, Spencer Rose, Josephine Mak, Sammantha B. Fuller, Angela Hunt, Jennifer L. Kuntz, Shawn Beitel, Young M. Yoo, Pearl Q. Zheng, Gayatri Arani, Julie Mayo Lamberte, Taylor Edwards, Mark G. Thompson, Ryan Sprissler, Natalie J. Thornburg, Ashley A. Lowe, Tamara Pilishvili, Jennifer L. Uhrlaub, Karen Lutrick, Jefferey L. Burgess, Ashley L. Fowlkes

Summary: Based on a study of healthcare personnel and frontline workers in six US states, it was found that a third dose of mRNA vaccine typically elicited a robust humoral immune response among those who had received primary vaccination. However, individuals who were infected with SARS-CoV-2 within three months before the third dose did not show a significant increase in antibody concentrations.

CLINICAL INFECTIOUS DISEASES (2023)

Article Medicine, General & Internal

Household Transmission of Influenza A Viruses in 2021-2022

Melissa A. Rolfes, H. Keipp Talbot, Huong Q. McLean, Melissa S. Stockwell, Katherine D. Ellingson, Karen Lutrick, Natalie M. Bowman, Emily E. Bendall, Ayla Bullock, James D. Chappell, Jessica E. Deyoe, Julie Gilbert, Natasha B. Halasa, Kimberly E. Hart, Sheroi Johnson, Ahra Kim, Adam S. Lauring, Jessica T. Lin, Christopher J. Lindsell, Son H. McLaren, Jennifer K. Meece, Alexandra M. Mellis, Miriana Moreno Zivanovich, Constance E. Ogokeh, Michelle Rodriguez, Ellen Sano, Raul A. Silverio A. Francisco, Jonathan E. Schmitz, Celibell Y. Vargas, Amy Yang, Yuwei Zhu, Edward A. Belongia, Carrie Reed, Carlos G. Grijalva

Summary: The COVID-19 pandemic resulted in a decrease in global influenza virus infections. However, there was an increased risk of influenza virus infection during the 2021-2022 influenza season due to loss of natural immunity and antigenic changes in circulating viruses.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Article Critical Care Medicine

Perceived Hospital Stress, Severe Acute Respiratory Syndrome Coronavirus 2 Activity, and Care Process Temporal Variance During the COVID-19 Pandemic*

George L. Anesi, Adair Andrews, He Julia Bai, Pavan K. M. Bhatraju, David M. Brett-Major, M. Jana Broadhurst, Elizabeth Salvagio Campbell, J. Perren Cobb, Martin Gonzalez, Sonya D. Homami, Cameron D. Hypes, Amy J. Irwin, Christopher J. Kratochvil, Kelsey K. Krolikowski, Vishakha K. P. Kumar, Douglas P. A. Landsittel, Richard A. M. Lee, Janice M. Liebler, Karen T. Lutrick, Lucian T. M. Marts, Jarrod M. Mosier, Vikramjit Mukherjee, Radu Postelnicu, Valentina N. Rodina, Leopoldo N. E. Segal, Jonathan E. Sevransky, Christine Spainhour, Avantika M. Srivastava, Timothy M. Uyeki, Mark M. Wurfel, David Wyles, Laura Evans

Summary: This study aimed to understand the impact of the COVID-19 pandemic on hospital operations and its relationship with local viral activity. The results showed that hospitals experienced high stress in dealing with severe acute respiratory infection patients during the pandemic, and there were also some instances of care deviations. This stress was closely related to the stress in the wards and emergency departments, and it was influenced by the increase in local cases. After the peak of the Delta variant surge, the overall hospital stress persisted for a certain period of time, while the stress in the ICU and emergency departments resolved relatively earlier. Similar patterns were observed during the Omicron BA.1 subvariant surge.

CRITICAL CARE MEDICINE (2023)

Article Health Care Sciences & Services

Care trajectories for patients utilizing electronic visits for COVID-like symptoms in a large healthcare delivery system: May 2020-December 2021

Holly C. Groom, Phil Crawford, Eduardo Azziz-Baumgartner, Michelle L. Henninger, Ning Smith, Bianca Salas, Judy Donald, Allison L. Naleway

Summary: Using the Kaiser Permanente Northwest (KPNW) Electronic Health Record, this study explores how the online screening tool facilitated the management of COVID-19 patients. It was found that 30% of patients were managed through online visits, helping to reduce unnecessary in-person encounters. The screening tool proved effective in assisting thousands of patients and preserving pandemic surge capacity. Evaluation: 8/10.

JOURNAL OF TELEMEDICINE AND TELECARE (2023)

Article Infectious Diseases

Predictors of starting and stopping chemsex in men who have sex with men in England: findings from the AURAH2 prospective study

Robbie Hammond, Valentina Cambiano, Fiona C. Lampe, David Asboe, Amanda Clarke, Richard Gilson, Graham J. Hart, Ada Rose Miltz, Nneka Nwokolo, Anne M. Johnson, Andrew N. Phillips, Andrew Speakman, Gary Whitlock, Alison Rodger, Janey Sewell

Summary: A longitudinal study on 622 men who have sex with men (MSM) found that factors such as age, unemployment, smoking, recent condomless sex, recent STI, and postexposure prophylaxis (PEP) use were associated with starting chemsex. On the other hand, age over 40, condomless sex, and use of PEP and pre-exposure prophylaxis (PrEP) were associated with lower likelihood of stopping chemsex. These findings can help identify individuals at high risk of starting chemsex and provide an opportunity for sexual health services to intervene with risk reduction measures, especially PrEP.

SEXUALLY TRANSMITTED INFECTIONS (2023)

Article Critical Care Medicine

Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

Samuel M. Brown, Christina E. Barkauskas, Birgit Grund, Shweta Sharma, Andrew N. Phillips, Lindsay Leither, Ithan Peltan, Michael Lanspa, Daniel L. Gilstrap, Ahmad Mourad, Kathleen Lane, Jeremy R. Beitler, Alexis L. Serra, Ivan Garcia, Eyad Almasri, Mohamed Fayed, Kinsley Hubel, Estelle S. Harris, Elizabeth A. Middleton, Macy A. G. Barrios, Kusum S. Mathews, Neha N. Goel, Samuel Acquah, Jarrod Mosier, Cameron Hypes, Elizabeth Salvagio Campbell, Akram Khan, Catherine L. Hough, Jennifer G. Wilson, Joseph E. Levitt, Abhijit Duggal, Siddharth Dugar, Andrew J. Goodwin, Charles Terry, Peter Chen, Sam Torbati, Nithya Iyer, Uriel S. Sandkovsky, Nicholas J. Johnson, Bryce R. H. Robinson, Michaela Matthay, Neil Raggarwal, Ivors Douglas, Jonathan Casey, Manuel Hache-Marliere, J. Georges Youssef, William Nkemdirim, Brad Leshnower, Omar Awan, Sonal Pannu, Darragh Shane O'Mahony, Prasad Manian, J. W. Awori Hayanga, Glenn W. Wortmann, Bruno M. Tomazini, Robert F. Miller, Jens-Ulrik Jensen, Daniel Murray, Nina A. Bickell, Jigna Zatakia, Sarah Burris, Elizabeth S. Higgs, Ven Natarajan, Robin L. Dewar, Adam Schechner, Nayon Kang, Alejandro Arenas-Pinto, Fleur Hudson, Adit A. Ginde, Wesley H. Self, Angela J. Rogers, Cathryn F. Oldmixon, Haley Morin, Adriana Sanchez, Amy C. Weintrob, Alexandre Biasi Cavalcanti, Anne Davis-Karim, Nicole Engen, Eileen Denning, B. Taylor Thompson, Annetine C. Gelijns, Virginia Kan, Victoria J. Davey, Jens Lundgren, Abdel G. Babiker, James Neaton, H. Clifford Lane

Summary: This study evaluated the efficacy of aviptadil in treating acute hypoxemic respiratory failure in COVID-19 patients. The results showed no significant difference in the primary efficacy outcome at day 90 compared to placebo, and there was also no significant difference in mortality between the two groups. The incidence of adverse events was similar in the aviptadil and placebo groups.

LANCET RESPIRATORY MEDICINE (2023)

Article Immunology

Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression

Jose R. Castillo-Mancilla, Mary Morrow, Peter W. Hunt, Samuel R. Schnittman, Andrew N. Phillips, Jason Baker, Jessica E. Haberer, Maria Joao Janeiro, Filipa Aragao, Cal Cohen, Nicholas Musinguzi, Todd T. Brown, Matthias Cavassini, Tracy R. Glass, Sergio Serrano-Villar, Samantha Mawhinney, Mark Siedner

Summary: Incomplete antiretroviral therapy (ART) adherence has been linked to adverse outcomes in people with HIV. The impact of improving adherence on the risk of severe non-AIDS events (SNAEs) and death is unknown.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Estimating the hospital costs of care for people living with HIV in England using routinely collected data

Alec Miners, Fiona C. Lampe, Valentina Cambiano, Achim Schwenk, Alison Rodger, Zia Sadique, Sophia Rein, Valerie Delpech, Andrew N. Phillips

Summary: This study aims to understand the healthcare activity and costs associated with caring for people living with HIV. The findings suggest that CD4 cell count and new patient status are the strongest predictors of hospital activity and costs. Demographic factors have weaker associations with costs and activity. These results can be used in future economic evaluations and budget planning.

HIV MEDICINE (2023)

Article Infectious Diseases

Understanding experiences of potential harm among MSM (cis and trans) using HIV self-testing in the SELPHI randomised controlled trial in England and Wales: a mixed-methods study

T. Charles Witzel, Emily Jay Nicholls, Leanne McCabe, Peter Weatherburn, Sheena McCormack, Christopher Bonell, Mitzy Gafos, Fiona C. Lampe, Andrew Speakman, David Dunn, Denise Ward, Andrew N. Phillips, Roger Pebody, Michelle M. Gabriel, Yolanda Collaco-Moraes, Alison J. Rodger, Fiona M. Burns

Summary: This study investigates the relationship between HIV self-testing (HIVST) and harm. The findings show that harms in HIVST are rare, with the potential sources of harm being the testing kit itself, the intervention measures, or the social context of the participants.

SEXUALLY TRANSMITTED INFECTIONS (2023)

Article Immunology

Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers

Katherine D. Ellingson, James Hollister, Cynthia J. Porter, Sana M. Khan, Leora R. Feldstein, Allison L. Naleway, Manjusha Gaglani, Alberto J. Caban-Martinez, Harmony L. Tyner, Ashley A. Lowe, Lauren E. W. Olsho, Jennifer Meece, Sarang K. Yoon, Josephine Mak, Jennifer L. Kuntz, Natasha Schaefer Solle, Karley Respet, Zoe Baccam, Meredith G. Wesley, Matthew S. Thiese, Young M. Yoo, Marilyn J. Odean, Flavia N. Miiro, Steve L. Pickett, Andrew L. Phillips, Lauren Grant, James K. Romine, Meghan K. Herring, Kurt T. Hegmann, Julie Mayo Lamberte, Brian Sokol, Krystal S. Jovel, Mark G. Thompson, Patrick Rivers, Tamara Pilishvili, Karen Lutrick, Jefferey L. Burgess, Claire M. Midgley, Ashley L. Fowlkes

Summary: This study found that among previously infected essential workers in the United States, risk factors for reinfection included being unvaccinated, infrequent mask use, time since first infection, and being non-Hispanic Black. Protecting workers from reinfection requires a multipronged approach including up-to-date vaccination, mask use as recommended, and reduction in underlying health disparities.

EMERGING INFECTIOUS DISEASES (2023)

Article Public, Environmental & Occupational Health

Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis

Andrew N. Phillips, Loveleen Bansi-Matharu, Maryam Shahmanesh, James R. Hargreaves, Jennifer Smith, Paul Revill, Euphemia Sibanda, Peter Ehrenkranz, Kenly Sikwese, Alison Rodger, Jens Lundgren, Charles F. Gilks, Catherine Godfrey, Frances Cowan, Valentina Cambiano

Summary: Providing free post-exposure prophylaxis medication to communities without prescription can reduce the incidence of HIV to some extent, but further pilot projects are needed to assess its effectiveness and cost-effectiveness.

LANCET GLOBAL HEALTH (2023)

暂无数据